Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Viatris Inc — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $79.51, while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Global X Robo Global Robotics & Automation ETF pays none, and Viatris Inc is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| ROBO | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $17.39 |
52-Week Low | $61.34 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO Global Robotics and Automation Index ETF trades at $77.31, down 0.74% with a bearish technical signal from moving averages. The ETF provides diversified exposure to robotics and AI themes with 79 holdings across machinery and electronic equipment sectors. Recent index rebalancing has shifted weight toward AI infrastructure and physical automation themes, reflecting evolving technology trends.
The ETF offers growth exposure to the expanding physical AI ecosystem but faces cyclical risks from industrial markets. While thematic positioning remains relevant, valuation concerns exist with a 24.9x P/E ratio. Key catalysts include AI infrastructure development and reshoring trends, though competition and market volatility present ongoing challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
